Ligand Design to Target and Modulate Metal–Protein Interactions in Neurodegenerative Diseases

Michael Beck; Amit S. Pithadia; Alaina DeToma; Kyle J. Korshavn; Mi Hee Lim

Ligand Design to Target and Modulate Metal–Protein Interactions in Neurodegenerative Diseases

Michael Beck, Amit S. Pithadia, Alaina DeToma, Kyle J. Korshavn, Mi Hee Lim

Eastern Illinois University

University of Michigan

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

<div class="line" id="line-13"> <span style='color: rgb(28, 29, 30); font-family: "Open Sans", icomoon, sans-serif; font-size: 16px;'> Aberrant metal&hyphen;protein interactions have been implicated in the pathogenesis of human neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Prion disease, Huntington's disease, and amyotrophic lateral sclerosis. Consequently, small molecules capable of targeting and modulating these metal&hyphen;protein interactions have been developed as chemical tools to elucidate their links to neurodegeneration and as drug candidates. In this chapter, the approaches employed for designing such molecules are discussed in the context of the current understanding of metal&hyphen;protein interactions in multiple neurodegenerative diseases. </span></div>

Original language	American English
Title of host publication	Ligand Design in Medicinal Inorganic Chemistry
State	Published - May 2 2014

Keywords

Alzheimer's disease
Amyloid‐β
Amyotrophic lateral sclerosis
Chemical tools
Huntington's Disease
Parkinson's Disease
Prion Disease
Prion Protein
Small molecules
Superoxide dismutase
a-Synuclein
Tau
Therapeutics

Disciplines

Chemistry

Cite this

@inbook{cb355dba9c934d1784e22308818190b5,

title = "Ligand Design to Target and Modulate Metal–Protein Interactions in Neurodegenerative Diseases",

abstract = " Aberrant metal&hyphen;protein interactions have been implicated in the pathogenesis of human neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Prion disease, Huntington's disease, and amyotrophic lateral sclerosis. Consequently, small molecules capable of targeting and modulating these metal&hyphen;protein interactions have been developed as chemical tools to elucidate their links to neurodegeneration and as drug candidates. In this chapter, the approaches employed for designing such molecules are discussed in the context of the current understanding of metal&hyphen;protein interactions in multiple neurodegenerative diseases. ",

keywords = "Alzheimer's disease, Amyloid‐β, Amyotrophic lateral sclerosis, Chemical tools, Huntington's Disease, Parkinson's Disease, Prion Disease, Prion Protein, Small molecules, Superoxide dismutase, a-Synuclein, Tau, Therapeutics",

author = "Michael Beck and Pithadia, {Amit S.} and Alaina DeToma and Korshavn, {Kyle J.} and Lim, {Mi Hee}",

note = "Department of Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan, 48109, USA Life Sciences Institute, University of Michigan, 210 Washtenaw Avenue, Ann Arbor, Michigan, 48109, USA Department of Chemistry, Ulsan National Institute of Science and Technology (UNIST), 50 UNIST‐gil, Eonyan‐eup, Ulju‐gun, Ulsan, 698‐798, Korea Search for more papers by this author",

year = "2014",

month = may,

day = "2",

language = "American English",

booktitle = "Ligand Design in Medicinal Inorganic Chemistry",

}

TY - CHAP

T1 - Ligand Design to Target and Modulate Metal–Protein Interactions in Neurodegenerative Diseases

AU - Beck, Michael

AU - Pithadia, Amit S.

AU - DeToma, Alaina

AU - Korshavn, Kyle J.

AU - Lim, Mi Hee

N1 - Department of Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan, 48109, USA Life Sciences Institute, University of Michigan, 210 Washtenaw Avenue, Ann Arbor, Michigan, 48109, USA Department of Chemistry, Ulsan National Institute of Science and Technology (UNIST), 50 UNIST‐gil, Eonyan‐eup, Ulju‐gun, Ulsan, 698‐798, Korea Search for more papers by this author

PY - 2014/5/2

Y1 - 2014/5/2

N2 - Aberrant metal&hyphen;protein interactions have been implicated in the pathogenesis of human neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Prion disease, Huntington's disease, and amyotrophic lateral sclerosis. Consequently, small molecules capable of targeting and modulating these metal&hyphen;protein interactions have been developed as chemical tools to elucidate their links to neurodegeneration and as drug candidates. In this chapter, the approaches employed for designing such molecules are discussed in the context of the current understanding of metal&hyphen;protein interactions in multiple neurodegenerative diseases.

AB - Aberrant metal&hyphen;protein interactions have been implicated in the pathogenesis of human neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Prion disease, Huntington's disease, and amyotrophic lateral sclerosis. Consequently, small molecules capable of targeting and modulating these metal&hyphen;protein interactions have been developed as chemical tools to elucidate their links to neurodegeneration and as drug candidates. In this chapter, the approaches employed for designing such molecules are discussed in the context of the current understanding of metal&hyphen;protein interactions in multiple neurodegenerative diseases.

KW - Alzheimer's disease

KW - Amyloid‐β

KW - Amyotrophic lateral sclerosis

KW - Chemical tools

KW - Huntington's Disease

KW - Parkinson's Disease

KW - Prion Disease

KW - Prion Protein

KW - Small molecules

KW - Superoxide dismutase

KW - a-Synuclein

KW - Tau

KW - Therapeutics

UR - https://onlinelibrary.wiley.com/doi/10.1002/9781118697191.ch10

M3 - Chapter

BT - Ligand Design in Medicinal Inorganic Chemistry

ER -

Ligand Design to Target and Modulate Metal–Protein Interactions in Neurodegenerative Diseases

Abstract

Keywords

Disciplines

Other files and links

Cite this